HBIO Quote, Financials, Valuation and Earnings

Bionano Genomics, Inc. has a net margin of -5.98% compared to Harvard Bioscience, Inc.'s net margin of -115.42%. Harvard Bioscience, Inc.'s return on equity of -155.33% beat Bionano Genomics, Inc.'s return on equity of -84.77%.

Harvard Bioscience, Inc. has a consensus price target of $2.00, signalling upside risk potential of 177.47%. On the other hand Bionano Genomics, Inc. has an analysts' consensus of $7.50 which suggests that it could grow by 377.71%. Given that Bionano Genomics, Inc. has higher upside potential than Harvard Bioscience, Inc., analysts believe Bionano Genomics, Inc. is more attractive than Harvard Bioscience, Inc..

Harvard Bioscience, Inc. has a beta of 1.531, which suggesting that the stock is 53.123% more volatile than S&P 500. In comparison Bionano Genomics, Inc. has a beta of 2.336, suggesting its more volatile than the S&P 500 by 133.592%.

Harvard Bioscience, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bionano Genomics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Harvard Bioscience, Inc. pays -- of its earnings as a dividend. Bionano Genomics, Inc. pays out -- of its earnings as a dividend.

Harvard Bioscience, Inc. quarterly revenues are $20.6M, which are larger than Bionano Genomics, Inc. quarterly revenues of $7.4M. Harvard Bioscience, Inc.'s net income of -$1.2M is higher than Bionano Genomics, Inc.'s net income of -$8.5M. Notably, Harvard Bioscience, Inc.'s price-to-earnings ratio is -- while Bionano Genomics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harvard Bioscience, Inc. is 0.37x versus 0.18x for Bionano Genomics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Bruker Corp. has a net margin of -5.98% compared to Harvard Bioscience, Inc.'s net margin of -6.8%. Harvard Bioscience, Inc.'s return on equity of -155.33% beat Bruker Corp.'s return on equity of -1.2%.

Harvard Bioscience, Inc. has a consensus price target of $2.00, signalling upside risk potential of 177.47%. On the other hand Bruker Corp. has an analysts' consensus of $51.79 which suggests that it could grow by 6.18%. Given that Harvard Bioscience, Inc. has higher upside potential than Bruker Corp., analysts believe Harvard Bioscience, Inc. is more attractive than Bruker Corp..

Harvard Bioscience, Inc. has a beta of 1.531, which suggesting that the stock is 53.123% more volatile than S&P 500. In comparison Bruker Corp. has a beta of 1.174, suggesting its more volatile than the S&P 500 by 17.405%.

Harvard Bioscience, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bruker Corp. offers a yield of 0.42% to investors and pays a quarterly dividend of $0.05 per share. Harvard Bioscience, Inc. pays -- of its earnings as a dividend. Bruker Corp. pays out 26.44% of its earnings as a dividend. Bruker Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Harvard Bioscience, Inc. quarterly revenues are $20.6M, which are smaller than Bruker Corp. quarterly revenues of $860.5M. Harvard Bioscience, Inc.'s net income of -$1.2M is higher than Bruker Corp.'s net income of -$58.5M. Notably, Harvard Bioscience, Inc.'s price-to-earnings ratio is -- while Bruker Corp.'s PE ratio is 77.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harvard Bioscience, Inc. is 0.37x versus 2.12x for Bruker Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Kestra Medical Technologies Ltd. has a net margin of -5.98% compared to Harvard Bioscience, Inc.'s net margin of -145.29%. Harvard Bioscience, Inc.'s return on equity of -155.33% beat Kestra Medical Technologies Ltd.'s return on equity of -105.99%.

Harvard Bioscience, Inc. has a consensus price target of $2.00, signalling upside risk potential of 177.47%. On the other hand Kestra Medical Technologies Ltd. has an analysts' consensus of $29.14 which suggests that it could grow by 5.78%. Given that Harvard Bioscience, Inc. has higher upside potential than Kestra Medical Technologies Ltd., analysts believe Harvard Bioscience, Inc. is more attractive than Kestra Medical Technologies Ltd..

Harvard Bioscience, Inc. has a beta of 1.531, which suggesting that the stock is 53.123% more volatile than S&P 500. In comparison Kestra Medical Technologies Ltd. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Harvard Bioscience, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kestra Medical Technologies Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Harvard Bioscience, Inc. pays -- of its earnings as a dividend. Kestra Medical Technologies Ltd. pays out 1.45% of its earnings as a dividend. Kestra Medical Technologies Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Harvard Bioscience, Inc. quarterly revenues are $20.6M, which are smaller than Kestra Medical Technologies Ltd. quarterly revenues of $22.6M. Harvard Bioscience, Inc.'s net income of -$1.2M is higher than Kestra Medical Technologies Ltd.'s net income of -$32.8M. Notably, Harvard Bioscience, Inc.'s price-to-earnings ratio is -- while Kestra Medical Technologies Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harvard Bioscience, Inc. is 0.37x versus 19.05x for Kestra Medical Technologies Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Precipio, Inc. has a net margin of -5.98% compared to Harvard Bioscience, Inc.'s net margin of -1.17%. Harvard Bioscience, Inc.'s return on equity of -155.33% beat Precipio, Inc.'s return on equity of -10.15%.

Harvard Bioscience, Inc. has a consensus price target of $2.00, signalling upside risk potential of 177.47%. On the other hand Precipio, Inc. has an analysts' consensus of -- which suggests that it could fall by -18.42%. Given that Harvard Bioscience, Inc. has higher upside potential than Precipio, Inc., analysts believe Harvard Bioscience, Inc. is more attractive than Precipio, Inc..

Harvard Bioscience, Inc. has a beta of 1.531, which suggesting that the stock is 53.123% more volatile than S&P 500. In comparison Precipio, Inc. has a beta of 1.085, suggesting its more volatile than the S&P 500 by 8.543%.

Harvard Bioscience, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Precipio, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Harvard Bioscience, Inc. pays -- of its earnings as a dividend. Precipio, Inc. pays out -- of its earnings as a dividend.

Harvard Bioscience, Inc. quarterly revenues are $20.6M, which are larger than Precipio, Inc. quarterly revenues of $6.8M. Harvard Bioscience, Inc.'s net income of -$1.2M is lower than Precipio, Inc.'s net income of -$79K. Notably, Harvard Bioscience, Inc.'s price-to-earnings ratio is -- while Precipio, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harvard Bioscience, Inc. is 0.37x versus 1.59x for Precipio, Inc.. Usually stocks with elevated PS ratios are considered overvalued.